Abstracts tagged "Outcome measures"

Abstract Number: 1540 • ACR Convergence 2022
Correlations of Soluble Interleukin-2 Receptor Serum Levels with Markers of Inflammation and Pathological High-sensitivity Troponin T and Its Possible Role as a Predictor of Early Clinical Progress in Systemic Sclerosis
Luise Schumacher¹, Sebastian Klapa², Antje Mueller³ and Gabriela Riemekasten⁴, ¹University of Lübeck, Lübeck, Germany, ²Universityhospital Schleswig-Holstein; University of Lübeck; Clinic of Rheumatology and Clinical Immunology, Luebeck, Germany, ³University Hospital Schleswig-Holstein (UKSH), Lübeck, ⁴University Clinic Schleswit-Holstein (UKSH), Luebeck, Germany
Background/Purpose: Systemic sclerosis (SSc) is characterized by chronic inflammation leading to damage of the vascular endothelium and excessive collagen deposition in several target organs. The…
Abstract Number: 1974 • ACR Convergence 2022
Which ACR Response Definition Should Be Used for Disease Activity Claims in Approval Studies of Rheumatoid Arthritis? A Systematic Evaluation
Andreas Kerschbaumer¹, Victoria Konzett², Josef Smolen¹ and Daniel Aletaha³, ¹Medical University of Vienna, Vienna, Austria, ²Division of Rheumatology / Department of Medicine III / Medical University of Vienna, Vienna, Austria, ³Medical University Vienna, Wien, Austria
Background/Purpose: The American College of Rheumatology (ACR) response definition was developed in 1995 by Felson et al. as a composite outcome and has been the…
Abstract Number: 2142 • ACR Convergence 2022
Strong Correlation Between Short- vs Long-form Composite Measures of Psoriatic Arthritis Disease Activity in a TNFi-IR Population Treated with Guselkumab: Data from the Phase 3b COSMOS Trial
William Tillett¹, Laura Coates², Mohamed Sharaf³, Marlies Neuhold⁴, Elke Theander⁵, Paul Bergmans⁶, May Shawi⁷, Michelle Perate⁸, Christine Contré⁹ and Philip Helliwell¹⁰, ¹Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, ⁴Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁵Formerly at Janssen Scientific Affairs, LLC, Solna, Sweden, ⁶Formerly at Janssen, Breda, Netherlands, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸Janssen Scientific Affairs, LLC, Horsham, PA, ⁹Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, ¹⁰Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Accurate assessment of psoriatic arthritis (PsA) disease activity in clinical practice requires a feasible, continuous, multidimensional composite instrument to assess key domains of this…
Abstract Number: 0192 • ACR Convergence 2022
Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis
Laura Coates¹, Arthur Kavanaugh², Erin McDearmon-Blondell³, Arthur Mandelin⁴, Tianming Gao⁵ and William Tillett⁶, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ²University of California San Diego, La Jolla, CA, ³AbbVie, Inc., Mettawa, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵AbbVie, Inc., North Chicago, IL, ⁶Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: RAPID3 (Routine Assessment of Patient Index Data 3) is a disease activity index calculated from 3 patient-reported measures: physical function, pain, and patient global…
Abstract Number: 0423 • ACR Convergence 2022
Direct and Indirect Effect of TNFi on BASMI Components in People with Axial Spondyloarthritis: A Longitudinal Study
Ana Pinto¹, Claire Harris², Rhys Hayward², Andrew Keat² and Pedro Machado², ¹Local Health Unit of Guarda, Barcelos, Portugal, ²Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, United Kingdom
Background/Purpose: The Bath Ankylosing Spondylitis Metrology Index (BASMI) is an index of spinal mobility for people with axial spondyloarthritis (axSpA). BASMI is one of the…
Abstract Number: 0940 • ACR Convergence 2022
Effect of an 8-week Tailored Physical Therapy Program on Sexual Function in Women with Systemic Sclerosis and Idiopathic Inflammatory Myopathies: A Pilot Controlled Study
Barbora Hermankova¹, Maja Spiritovic¹, Sabina Oreska², Hana Storkanova², Karel Pavelka³, Ladislav Šenolt⁴, Jiří Vencovský⁴, Radim Becvar² and Michal Tomcik², ¹Institute of Rheumatology, Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Systemic rheumatic diseases like systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM) may affect all aspects of life, including sexual health. However, no non-pharmacological…
Abstract Number: 1268 • ACR Convergence 2022
Evaluating Numeric Rating Scale Versions of the 3 and 4 Visual Analog Scale (3/4-VAS) Composite Measures in Patients with Active Psoriatic Arthritis from the SELECT-PsA Program
William Tillett¹, Laura Coates², Mitsumasa Kishimoto³, Arathi Setty⁴, Tianming Gao⁵, Ralph Lippe⁶ and Philip Helliwell⁷, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Kyorin University School of Medicine, Yokohama, Japan, ⁴AbbVie, Inc., Staten Island, NY, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc, Wiesbaden, Germany, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Composite measures using 3-visual analog scale (VAS; physician's global assessment, patient's global assessment, and skin) or 4-VAS (physician's global assessment, joints, skin, and pain)…
Abstract Number: 1595 • ACR Convergence 2022
Association of Sustained Lupus Low Disease Activity State with Improved Outcomes in SLE: A Multinational Prospective Cohort Study
Vera Golder¹, Rangi Kandane-Rathnayake¹, Ning Li¹, Worawit Louthrenoo², Yi-Hsing Chen³, Jiacai Cho⁴, Aisha Lateef⁵, Laniyati Hamijoyo⁶, Luo Shue Fen⁷, Yeong-Jian Wu⁷, Sandra Navarra⁸, Leonid Zamora⁸, Zhanguo Li⁹, An Yuan¹⁰, Sargunan Sockalingam¹¹, Yasuhiro Katsumata¹², Masayoshi Harigai¹², Yanjie Hao¹³, Zhouli Zhang¹⁴, Duminda Basnayake¹⁵, Madelynn Chan¹⁶, Jun Kikuchi¹⁷, Tsutomu Takeuchi¹⁸, Sang-Cheol Bae¹⁹, Fiona Goldblatt²⁰, Shereen Oon²¹, Sean O'Neill²², Kathryn Gibson²², Kristine Ng²³, Hui Nee Annie Law²⁴, Nicole Tugnet²⁵, Sunil Kumar²⁶, Cherica Tee²⁷, Michael Tee²⁷, Yoshiya Tanaka²⁸, Chak Sing²⁹, Alberta Hoi³⁰, Mandana Nikpour³¹ and Eric Morand³², ¹Monash University, Clayton, Australia, ²Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, ³Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ⁴National University Health System (NUHS), Singapore, Singapore, ⁵National University Hospital, Singapore, Singapore, ⁶Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, ⁷Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁸University of Santo Tomas, Manila, Philippines, ⁹Peking University People's Hospital, Beijing, China, ¹⁰Peking University Health Science Center, Beijing, China, ¹¹University of Malaya, Kuala Lumpur, Kuala Lumpur, Malaysia, ¹²Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ¹³The University of Melbourne, Melbourne, Australia, ¹⁴Peking University First Hospital, Beijing, China, ¹⁵Teaching Hospital Kandy, Kandy, Sri Lanka, ¹⁶Tan Tock Seng Hospital, Singapore, Singapore, ¹⁷Keio University School of Medicine, Tokyo, Japan, ¹⁸Keio University and Saitama Medical University, Tokyo, Japan, ¹⁹Hanyang University Medical Center, Seoul, Republic of Korea, ²⁰Flinders Medical Centre, Adelaide, Australia, ²¹St Vincent's Hospital, Fitzroy, Australia, ²²Liverpool Hospital, Sydney, Australia, ²³North Shore Hospital, Auckland, New Zealand, ²⁴Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ²⁵Greenlane Clinical Centre, Auckland, New Zealand, ²⁶Middlemore Hospital, Auckland, New Zealand, ²⁷University of the Philippines, Quezon City, Philippines, ²⁸University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ²⁹The University of Hong Kong, Pok Fu Lam, Hong Kong, ³⁰Monash Health, Melbourne, Australia, ³¹The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia, ³²Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia
Background/Purpose: Since the initial prospective validation of the Lupus Low Disease Activity State (LLDAS), this treat-to-target endpoint has been studied in numerous other cohorts, with…
Abstract Number: 1990 • ACR Convergence 2022
Artificial Intelligence Applied to Transcriptomics Profiling of Synovial Tissue Biopsies Accurately Predicts Rheumatoid Arthritis Patients Who Will Respond or Be Refractory to Standard Biological Treatments
Giorgio CASABURI, Todd Holscher and Ming-Chou Lee, Exagen, Inc., Vista, CA
Background/Purpose: In recent years, biological therapies have revolutionized treatments of Rheumatoid Arthritis (RA). However, about 40% of RA patients do not respond to given biologics…
Abstract Number: 2170 • ACR Convergence 2022
Validation of Ranked Composite Important Difference (RCID) Score in Early Diffuse Cutaneous Systemic Sclerosis
Francesco Del Galdo¹, Suiyuan Huang², Lesley-Anne Bissell³, sindhu johnson⁴, Daniel Furst⁵ and Dinesh Khanna⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, ²University of Michigan, Ann Arbor, MI, ³University of Leeds, Leeds, United Kingdom, ⁴Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Toronto Western Hospital, Mount Sinai Hospital; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵University of California Los Angeles, Los Angeles, CA, ⁶Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: The Ranked Composite Important Difference (RCID) in diffuse cutaneous Systemic Sclerosis ( dcSSc) is a clinically and patient meaningful composite score for outcome of…
Abstract Number: 0207 • ACR Convergence 2022
Novel Digital Technologies for the Assessment of Objective Measures and PROs in Patients with Rheumatoid Arthritis: A Pilot Study Using Smart Devices and a Bespoke Mobile App
Valentin Hamy¹, Christopher Llop², Christopher W Yee², Luis Garcia-Gancedo³, Aoife Maxwell⁴, Wen-Hung Chen⁵, Ryan Tomlinson³, Priyanka Bobbili², Julien Bendelac², Jessica Landry², Maral DerSarkissian⁶, Mihran Yenikomshian², Elinor A Mody⁷, Mei Sheng Duh² and Rachel Williams³, ¹GlaxoSmithKline, London, United Kingdom, ²Analysis Group Inc, Boston, MA, ³GlaxoSmithKline, Philadephia, ⁴GlaxoSmithKline, Stevenage, United Kingdom, ⁵GlaxoSmithKline, Value Evidence and Outcomes, Philadephia, ⁶Analysis Group Inc, Los Angeles, CA, ⁷Reliant Medical Group, Worcester, MA
Background/Purpose: RA symptoms are typically only assessed intermittently in clinical practice and clinical trials. Digital technologies (wearables, smartphones) can facilitate continuous remote monitoring of patients'…
Abstract Number: 0441 • ACR Convergence 2022
Patient-Reported Outcomes in ANCA-Associated Vasculitis: Interactions Between Patients’ and Physicians’ Perspectives in a Mexican Cohort
José Joel Hurtado-Arias¹, Isabela Ramírez-Mulhern², Javier Merayo-Chalico³, Carlos A. Gonzalez-Martinez⁴, Ana Barrera-Vargas² and Andrea Hinojosa-Azaola¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de México, Mexico, ⁴Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico
Background/Purpose: The antineutrophil cytoplasm antibody (ANCA) associated vasculitis (AAV) are a group of complex chronic diseases resulting in morbidity, accumulated organ damage, treatment burden, and…
Abstract Number: 0993 • ACR Convergence 2022
SARS-CoV-2 Vaccine Side Effects and Infections in SLE
Laura Yan¹, Arielle Mendel², Evelyne Vinet², Fares Kalache³, Jennifer Lee¹, Popi Panaritis² and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Center, Montréal, QC, Canada
Background/Purpose: SLE patients are an especially vulnerable population in the face of the COVID pandemic due to their dysregulated endogenous immune system, further downregulated by…
Abstract Number: 1290 • ACR Convergence 2022
Inflammation Is More Prominent Than Joint Damage at Initial Visits of Patients with Inflammatory Arthritides, but Organ Damage and Patient Distress Are as Prominent in Overall Rheumatology Care: Data from a Feasible Physician RheuMetric Checklist
Juan Schmukler¹, Tengfei Li², Joel Block¹ and Theodore Pincus¹, ¹Rush University Medical Center, Chicago, IL, ²Georgetown University, Washington, DC
Background/Purpose: Most widely-used rheumatology indices, e.g., DAS28, CDAI, SLEDAI, ASDAS, DAPSA, reflect the mission of rheumatologists to control inflammatory activity (INF) to prevent subsequent organ…
Abstract Number: 1597 • ACR Convergence 2022
Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial
Frank Behrens¹, Peter Taylor², Philip J Mease³, Paul Peloso⁴, Dieter Wetzel⁵, Nicolai Brun⁵, Brian Wiens⁶, Jan Brandt-Juergens⁷, Edit Drescher⁸, Eva Dokoupilova⁹, Anna Rowińska-Osuch¹⁰, Nadia Abdel- Kader Martin¹¹ and Kurt de Vlam¹², ¹Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ²University of Oxford, Oxford, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴ACELYRIN, Naples, FL, ⁵Affibody AB, Solna, Sweden, ⁶ACELYRIN, Inc., Los Angeles, CA, ⁷Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁸Veszprem Megyei Csolnoky Ferenc Korhaz, Budapest, Hungary, ⁹Medical Plus, s.r.o. & Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Brno, Prague, Czech Republic, ¹⁰ETG Network - Rheumatology, Warsaw, Poland, ¹¹Hospital Infanta Luisa Quiron, Rheumatology, Sevilla, Spain, ¹²University Hospitals Leuven, Leuven, Belgium
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, inflammatory disease with multiple clinical manifestations (arthritis, spondylitis, enthesitis, dactylitis, skin, nails). IL-17 inhibitors have shown efficacy across…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].